Author: NewsEditor

The leading provider of court data workflow automation in the U.S. elevates security in the midst of state court expansion.

PacerPro SOC 2 Complian…

Recent Project: Robotic Sorting Facility
SOUTH BEND, Ind. – October 24, 2022 – (Newswire.com)
…

Bitcoin, Ethereum, and other cryptocurrencies are now being closely tracked by HackerNoon through Coin Pages powered by CoinMarketCap. Readers can view these pages to see daily changes in each coin’s price and market cap alongside recently published stories.

EDWARDS, Colo. – October 24, 2022 – (Newswire.com)

HackerNoon, a website focused on publishing stories about technology, has launched new coin pages to track popular cryptocurrencies such as Bitcoin and Ethereum. The coin data is constantly updated, tracking changes in each currency over a period of 24 hours.

“As the crypto space is evolving, so is HackerNoon,” wrote CEO David Smooke in an article announcing these new pages. “Our next step is to give our readers and writers better data within our technology publishing platform.”

By default, the list of coin pages is ranked according to market cap. “Too much of the crypto and mainstream media talk about Bitcoin breaking $10k, $20k, $50k,” wrote David, “but in reality, what they should be talking about is the market cap. This simple but important distinction is missed by most mainstream media.” Coins ranked at the top currently include Bitcoin, Ethereum, and XRP. Viewers can also sort this list by price and price change, as well as alphabetical order. 

The prices are tracked in collaboration with CoinMarketCap. Through combining their information with HackerNoon’s own engineering, each page contains a graph tracking changes in a currency’s price over time. These pages also provide information on each currency’s trading volume and circulating supply, giving readers the chance to see how each coin’s popularity has changed over time.

Coin pages will also help distribute stories written by HackerNoon contributors. Each currency on the list of pages is paired with the latest article that includes that currency as a topic. When viewing a page, it’s also possible to see a curated list of HackerNoon stories alongside stories from other websites surrounding the chosen coin. HackerNoon offers these stories as a way to help readers and hodlers keep track of trending topics in relation to various cryptocurrencies.

In the future, HackerNoon hopes to add detailed descriptions to every currency on the list, providing information on each coin’s history and milestones. Nearly every page contains a short description; more popular currencies have entire paragraphs detailing their criticisms and claims to fame.

“We’re concentrating on integrating more API-driven data sources about companies, cryptocurrencies, software and people,” wrote David. “These coin price pages will be a quantitative and qualitative destination to learn more about what’s happening with every top cryptocurrency.”

About HackerNoon 
HackerNoon is built for technologists to read, write, and publish. We are an international community of 30,000+ contributing writers and 4,000,000+ curious and insightful monthly readers. Get your technology story published today.

Contact Here | Email 
Visit us on social media: 
Facebook | Twitter | LinkedIn

Contact Information:

Limarc Ambalina

VP of Editorial

[email protected]

Press Release Service
by
Newswire.com

Original Source:

HackerNoon Introduces Coin Pages in Collaboration With CoinMarketCap to Track the Prices and Popularity of the Internet’s Biggest Cryptocurrencies

Emergency Planning Professional Emergency Planning Professional Banner
CHICAGO – October 24, 2022 – (Newswire.com)…

Gb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

LAS VEGAS – October 24, 2022 – (Newswire.com)

Gb Sciences, Inc. (“GbS”; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS’ proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS’ proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company’s first non-cannabis formulations to advance in preclinical studies.

“We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations,” said Dr. Andrea Small-Howard, Gb Sciences’ President and Chief Science Officer. “This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs.”

For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.

The PhAROS^TM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com. 

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Media Contact

Alexis Quintal

[email protected]

Contact Information:

Madeleine Moench

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

LONDON – October 24, 2022 – (Newswire.com)

Genomes.io is very happ…

Lookah, the award-winning vape and glass innovator, launches the Dragon Egg electronic dab rig.

Lookah Dragon Egg Dragon Egg Electronic Dab Rig …